Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Defence Therapeutics Inc
(CSE:
DTC
)
0.6300
+0.0100 (+1.61%)
Official Closing Price
Updated: 3:58 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,000
Open
0.6400
Bid (Size)
0.6300 (2,000)
Ask (Size)
0.6600 (20,000)
Prev. Close
0.6200
Today's Range
0.6300 - 0.6400
52wk Range
0.5500 - 3.040
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Precision Medicine Helps Conquer Advanced-Stage Cancer
November 14, 2023
As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According...
Via
PressReach
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
November 14, 2023
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in
Via
PressReach
Exposures
Product Safety
Performance
YTD
-73.08%
-73.08%
1 Month
-22.22%
-22.22%
3 Month
-46.15%
-46.15%
6 Month
-67.36%
-67.36%
1 Year
-76.75%
-76.75%
More News
Read More
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
Via
FinancialNewsMedia
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
November 07, 2023
Via
PressReach
Topics
Intellectual Property
Exposures
Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
Via
FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
October 18, 2023
Via
PressReach
Exposures
Product Safety
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Via
PressReach
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
October 17, 2023
Via
PressReach
Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
October 17, 2023
Via
PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Via
PressReach
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
October 10, 2023
Via
PressReach
Exposures
COVID-19
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
October 10, 2023
Via
PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
September 26, 2023
Via
PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
May 10, 2023
Via
Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
May 04, 2023
Via
Newsfile
Topics
Supply Chain
Exposures
Supply Chain
BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals
November 10, 2022
Via
Newsfile
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
September 29, 2022
Via
Newsfile
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
September 21, 2022
Via
Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
September 16, 2022
Via
Newsfile
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
July 06, 2021
Via
Newsfile
Exposures
COVID-19
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
June 29, 2021
Via
Newsfile
Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
June 22, 2021
Via
Newsfile
Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
June 07, 2021
Via
Newsfile
Exposures
Product Safety
RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
June 01, 2021
Via
Newsfile
Exposures
COVID-19
Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
May 31, 2021
Via
Newsfile
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.